No Data
No Data
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged
Businessolver Improves Access to Care Through Enhanced Provider Guidance
Is GoodRx Holdings (NASDAQ:GDRX) A Risky Investment?
Mizuho Initiates GoodRx Holdings at Neutral With $5 Price Target
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)